key: cord-0961712-1b6tdesz
authors: Wambier, Carlos Gustavo; Tosti, Antonella
title: Reply to early onset effluvium secondary to COVID-19 and body-hair effluvium
date: 2021-12-11
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2021.11.043
sha: 0e2f58b12a6416eefc8ab651bac509a33ea01b3b
doc_id: 961712
cord_uid: 1b6tdesz

nan

anagen effluvium in cases assumed to be acute telogen effluvium, particularly in the more 27 severe hospitalized cases, when associated with early onset. 28

Our previous article also showed a wide range of duration of the shedding: from 12 to 100 days. 29

Theoretically, the different duration of shedding could have an association with hair cycle phase 30 shedding (anagen vs telogen), and also the presence or not of chronic inflammation. 31

To further add to the list of differential diagnosis, for cases of later onset and longer duration, 32 manifesting clinically as alopecia (without expected regrowth of the hair shafts), alopecia areata 33 has been reported post-COVID-19 2 as a straightforward diagnosis of patchy areas of alopecia, 3 34 however, diffuse alopecia areata can be difficult to diagnose clinically and could be initially 35 misdiagnosed as chronic telogen effluvium. 

Early onset 70 effluvium secondary to COVID-19: A clinical and histological characterization

Dermatol. 2021;epub

New onset of alopecia areata in a patient with SARS-73

CoV-2 infection: Possible pathogenetic correlations?

Alopecia Areata after COVID-19: causal or casual 76 relationship?

Tofacitinib in Patients Hospitalized with Covid-79

Efficacy and safety of baricitinib for the 81 treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised